Intellia Therapeutics Completes Enrollment in Phase 3 Trial of Transthyretin Amyloidosis Treatment

10:35 AM EST, 11/04/2026 (MT Newswires) -- Intellia Therapeutics (NTLA) has completed the enrollment of its phase 3 clinical trial of nex-z in patients with transthyretin amyloidosis with polyneuropathy, the company said Wednesday. The MAGNITUDE-2 trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of nex-z in approximately 60 patients with the disease, according to a statement. Nex-z, an investigational in vivo CRISPR-based therapeutic candidate, offers the possibility of halting and reversing disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment, Intellia said. Price: 11.94, Change: +0.08, Percent Change: +0.67